{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,5]],"date-time":"2026-11-05T22:00:25Z","timestamp":1793916025739,"version":"4.8.0"},"reference-count":28,"publisher":"Informa UK Limited","issue":"11","license":[{"start":{"date-parts":[[2023,10,12]],"date-time":"2023-10-12T00:00:00Z","timestamp":1697068800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Current Medical Research and Opinion"],"published-print":{"date-parts":[[2023,11,2]]},"DOI":"10.1080\/03007995.2023.2262381","type":"journal-article","created":{"date-parts":[[2023,9,27]],"date-time":"2023-09-27T07:28:20Z","timestamp":1695799700000},"page":"1505-1511","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":5,"title":["Health-related quality-of-life in treatment-naive CLL\/SLL patients treated with zanubrutinib versus bendamustine plus rituximab"],"prefix":"10.1080","volume":"39","author":[{"given":"Paolo","family":"Ghia","sequence":"first","affiliation":[{"name":"Division of Experimental Oncology, Universit\u00e0 Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milano, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gisoo","family":"Barnes","sequence":"additional","affiliation":[{"name":"Health Economics and Outcomes Research, BeiGene USA, Inc, San Mateo, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Keri","family":"Yang","sequence":"additional","affiliation":[{"name":"Health Economics and Outcomes Research, BeiGene USA, Inc, San Mateo, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Constantine S.","family":"Tam","sequence":"additional","affiliation":[{"name":"The Alfred Hospital, Melbourne, VIC, Australia"},{"name":"Monash University, Clayton, VIC, Australia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tadeusz","family":"Robak","sequence":"additional","affiliation":[{"name":"Department of Hematology, Medical University of Lodz, Lodz, Poland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2040-4961","authenticated-orcid":false,"given":"Jennifer R.","family":"Brown","sequence":"additional","affiliation":[{"name":"Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brad S.","family":"Kahl","sequence":"additional","affiliation":[{"name":"Department of Medicine, Washington University School of Medicine, St Louis, MO, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tian","family":"Tian","sequence":"additional","affiliation":[{"name":"Health Economics and Outcomes Research, BeiGene USA, Inc, San Mateo, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andy","family":"Szeto","sequence":"additional","affiliation":[{"name":"Health Economics and Outcomes Research, BeiGene USA, Inc, San Mateo, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jason C.","family":"Paik","sequence":"additional","affiliation":[{"name":"Health Economics and Outcomes Research, BeiGene USA, Inc, San Mateo, CA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mazyar","family":"Shadman","sequence":"additional","affiliation":[{"name":"Clinical Research Division, Fred Hutchinson Cancer Center, Seattle, WA, USA"},{"name":"Department of Medicine, University of Washington, Seattle, WA, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2023,10,12]]},"reference":[{"key":"e_1_3_8_2_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12938-021-00973-6"},{"key":"e_1_3_8_3_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.annonc.2020.09.019"},{"key":"e_1_3_8_4_1","unstructured":"National Cancer Institute. SEER Cancer Stat Facts: chronic lymphocytic leukemia\/small lymphocytic lymphoma. [cited 2023 Jun 25]. Available from: https:\/\/seer.cancer.gov\/statfacts\/html\/cllsll.html"},{"key":"e_1_3_8_5_1","doi-asserted-by":"publisher","DOI":"10.1080\/03007995.2020.1784120"},{"key":"e_1_3_8_6_1","unstructured":"American Cancer Society. Signs and symptoms of chronic lymphocytic leukemia. [cited 2023 Jun 25]. Available from: https:\/\/www.cancer.org\/cancer\/chronic-lymphocytic-leukemia\/detection-diagnosis-staging\/signs-symptoms.html"},{"key":"e_1_3_8_7_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-015-1039-y"},{"key":"e_1_3_8_8_1","doi-asserted-by":"publisher","DOI":"10.1182\/hematology.2020000118"},{"key":"e_1_3_8_9_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2141.2007.06791.x"},{"key":"e_1_3_8_10_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11912-020-0881-4"},{"key":"e_1_3_8_11_1","doi-asserted-by":"publisher","DOI":"10.3390\/cancers13133134"},{"key":"e_1_3_8_12_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41375-019-0602-x"},{"key":"e_1_3_8_13_1","doi-asserted-by":"publisher","DOI":"10.1080\/10428194.2017.1416364"},{"key":"e_1_3_8_14_1","unstructured":"GlobeNewswire. BeiGene announces the approval of BRUKINSATM (zanubrutinib) in China for patients with relapsed\/refractory chronic lymphocytic leukemia or small lymphocytic lymphoma and relapsed\/refractory mantle cell lymphoma; 2020 [cited 2023 Jun 25]. Available from: https:\/\/www.globenewswire.com\/news-release\/2020\/06\/03\/2042805\/0\/en\/BeiGene-Announces-the-Approval-of-BRUKINSA-Zanubrutinib-in-Chinafor-Patients-with-Relapsed-Refractory-Chronic-Lymphocytic-Leukemia-or-Small-Lymphocytic-Lymphoma-and-Relapsed-Refra.html"},{"key":"e_1_3_8_15_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.9b00687"},{"key":"e_1_3_8_16_1","doi-asserted-by":"publisher","DOI":"10.1182\/blood.2020006844"},{"key":"e_1_3_8_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/s1470-2045(22)00293-5"},{"issue":"2","key":"e_1_3_8_18_1","first-page":"231","article-title":"International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use (ICH) adopts consolidated guideline on good clinical practice in the conduct of clinical trials on medicinal products for human use","volume":"48","year":"1997","unstructured":"International conference on harmonisation of technical requirements for registration of pharmaceuticals for human use (ICH) adopts consolidated guideline on good clinical practice in the conduct of clinical trials on medicinal products for human use. Int Dig Health Legis. 1997;48(2):231\u2013234.","journal-title":"Int Dig Health Legis"},{"key":"e_1_3_8_19_1","doi-asserted-by":"publisher","DOI":"10.1093\/jnci\/85.5.365"},{"key":"e_1_3_8_20_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-011-9903-x"},{"key":"e_1_3_8_21_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.1999.17.9.2932"},{"key":"e_1_3_8_22_1","volume-title":"Chronic lymphocytic leukemia\/small lymphocytic lymphoma","author":"NCCN Clinical Practice Guidelines in Oncology","year":"2022","unstructured":"NCCN Clinical Practice Guidelines in Oncology. Chronic lymphocytic leukemia\/small lymphocytic lymphoma. Plymouth Meeting (PA): National Comprehensive Cancer Network; 2022."},{"key":"e_1_3_8_23_1","doi-asserted-by":"publisher","DOI":"10.1200\/jco.1998.16.1.139"},{"key":"e_1_3_8_24_1","doi-asserted-by":"publisher","DOI":"10.1586\/14737167.2015.1115348"},{"key":"e_1_3_8_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/j.1524-4733.2007.00273.x"},{"key":"e_1_3_8_26_1","doi-asserted-by":"publisher","DOI":"10.3109\/10428194.2015.1070151"},{"key":"e_1_3_8_27_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11136-017-1718-y"},{"key":"e_1_3_8_28_1","doi-asserted-by":"publisher","DOI":"10.1080\/0284186x.2016.1205217"},{"key":"e_1_3_8_29_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa2201817"}],"container-title":["Current Medical Research and Opinion"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/03007995.2023.2262381","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,9,24]],"date-time":"2024-09-24T20:08:18Z","timestamp":1727208498000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/03007995.2023.2262381"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10,12]]},"references-count":28,"journal-issue":{"issue":"11","published-print":{"date-parts":[[2023,11,2]]}},"alternative-id":["10.1080\/03007995.2023.2262381"],"URL":"https:\/\/doi.org\/10.1080\/03007995.2023.2262381","relation":{},"ISSN":["0300-7995","1473-4877"],"issn-type":[{"value":"0300-7995","type":"print"},{"value":"1473-4877","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,10,12]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=icmo20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=icmo20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2023-07-26","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-09-19","order":1,"name":"revised","label":"Revised","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-09-20","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2023-10-12","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}